IN
Integrated BioPharma, Inc.
INBP · OTC
$0.18 +1.11% (+$0.00)
1M -3.23%
Market Cap $5.25M
P/E Ratio -
Div. Yield -
ROE 8.32%
Bulios Fair Price
$0.22
20.9% upside
Current Price
$0.18
Undervalued Fair Value Overvalued
According to Bulios Fair Price, INBP is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
69 /100
Cheap P/S 0.11x
P/B 0.28x
P/FCF 1.86x
Growth
9 /100
Declining Rev. growth 1.13%
FCF growth 19.59%
Book val. growth 3.03%
Profitability
13 /100
Weak Net margin 3.43%
Op. margin 2.58%
FCF margin 5.85%
Quality
15 /100
Poor ROE 8.32%
ROA 6.20%
Asset turnover 1.81x
Debt
100 /100
Low Current ratio 3.25x
Net debt/EBITDA -44.29x
Debt/Equity 0.18x
Stability
47 /100
Moderate Rev. volatility 8.97%
EPS volatility 373.01%
Profitable years 2
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INBP
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Riva Sheppard
Employees
153
Headquarters
Hillside